Pfizer's Chief Scientific Officer for Vaccine Research and Development advised the National Science Advisory Board for Biosecurity during the group's deliberation over redrafting government policies concerning gain of function research.
In light of these claims, the proximity of Pfizer's Philip Dormitzer to the U.S. government's effort to redraft its policies surrounding gain of function research in 2016 is curious, as he was working as the Vice President and Chief Scientific Officer for RNA and Viral Vaccines at Pfizer at the time.
In 2014, the U.S. government announced a pause on funding gain of function research while concurrently launching a deliberative process to develop a new policy aimed at better regulating the risky form of research.
The NSABB was responsible for "Providing the U.S. government with recommendations on policy for the funding and conduct of gain of function research" and "Serving as the official federal advisory body for providing advice on oversight of this area of dual use research."
Put simply, the National Academies were the most influential advisor to the NSABB, which, in turn, was responsible drafting the government's new gain of function research policy.
"Philip Dormitzer from the Pfizer Vaccine Research and Development Unit and a member of the Symposium Planning Committee, introduced the session as a continuation of the earlier plenary session on the U.S. policy landscape. This session would present the perspectives of several different key stakeholders, including regulatory agencies and the vaccine industry," explained the National Academy of Science's breakdown of the event.
"Philip Dormitzer pointed out that not all GOF research involves GOF studies of concern, and therefore not all the research needs to be overseen by any additional policy frameworks."
https://warroom.org/2023/02/07/pfizer-cso-helped-direct-governments-gof-policy/
No comments:
Post a Comment